Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases. [electronic resource]
Producer: 20171121Description: 458-466 p. digitalISSN:- 1556-1380
- Adenocarcinoma -- drug therapy
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Apoptosis
- B7-H1 Antigen -- metabolism
- Biomarkers, Tumor -- metabolism
- CD8-Positive T-Lymphocytes -- immunology
- Female
- Follow-Up Studies
- Humans
- Lung Neoplasms -- drug therapy
- Lymphatic Metastasis
- Lymphocytes, Tumor-Infiltrating -- immunology
- Male
- Middle Aged
- Neoplasm Recurrence, Local -- drug therapy
- Neoplasm Staging
- Prognosis
- Survival Rate
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.